Olopatadine Misom
Antihistamine Eye Drops 1 mg/ml for Seasonal Allergic Conjunctivitis
Quick Facts About Olopatadine Misom
Key Takeaways About Olopatadine Misom
- Dual-action relief: Olopatadine combines direct H1-receptor blockade with mast cell stabilisation, offering more comprehensive symptom control than single-action antihistamines
- Twice-daily dosing: Apply one drop in the affected eye(s) in the morning and evening, approximately 8 hours apart, for the duration of the allergy season
- Contact lens precaution: Remove contact lenses before each application and wait at least 15 minutes before reinserting them, because the preservative benzalkonium chloride can be absorbed by soft lenses
- Paediatric limits: Suitable from 3 years of age; Olopatadine Misom should not be used in children younger than 3 because safety and efficacy have not been established
- Open-bottle shelf life: Discard the bottle 4 weeks after first opening, even if solution remains, to prevent microbial contamination and eye infection
What Is Olopatadine Misom and What Is It Used For?
Olopatadine Misom is a topical ophthalmic solution containing the antihistamine olopatadine hydrochloride at a concentration of 1 mg/ml (0.1%). It is indicated for the treatment of the signs and symptoms of seasonal allergic conjunctivitis, a common eye condition triggered by airborne allergens such as tree and grass pollen, dust mites and pet dander.
Allergic conjunctivitis is one of the most common ocular conditions worldwide, affecting between 10% and 30% of the global population according to estimates from the World Allergy Organization (WAO). When an allergen encounters the conjunctiva – the thin transparent membrane that lines the inner eyelids and covers the white of the eye – the local immune system mounts a type I hypersensitivity reaction. Mast cells resident in the conjunctival tissue rapidly degranulate, releasing histamine together with other inflammatory mediators such as tryptase, prostaglandin D2, leukotrienes and pro-inflammatory cytokines. These mediators are responsible for the hallmark symptoms of itching, redness (conjunctival hyperaemia), watery eyes and swelling (chemosis).
Olopatadine belongs to a select group of topical antiallergic medicines that combine selective histamine H1-receptor antagonism with mast cell-stabilising activity. This dual pharmacological profile distinguishes olopatadine from many older first- and second-generation ophthalmic antihistamines, which typically act through only one of these mechanisms. By binding competitively to H1 receptors on sensory nerve endings and vascular endothelium, olopatadine directly blocks the itch, redness and vasodilatory signals produced by histamine. At the same time, it inhibits the calcium-dependent degranulation of conjunctival mast cells, reducing the release of newly formed inflammatory mediators before they can amplify the allergic response.
Because of this combined mechanism of action, olopatadine provides a rapid onset of relief – typically within a few minutes of instillation – together with a duration of effect of approximately 8 hours. This pharmacokinetic profile underpins the recommended twice-daily dosing regimen. Multiple randomised, placebo-controlled clinical trials using conjunctival allergen challenge (CAC) models and real-world pollen-exposure studies have shown that olopatadine 0.1% significantly reduces ocular itching, conjunctival redness, tearing and eyelid swelling compared with placebo. Head-to-head comparisons have shown that olopatadine is at least as effective as other dual-action topical antihistamines such as ketotifen and azelastine, and more effective than older single-action products such as levocabastine in controlling allergic eye symptoms.
Olopatadine Misom is a generic ophthalmic formulation containing the same active substance and strength (1 mg/ml) as the originator reference product. Generic ophthalmic medicines are required to meet the same pharmaceutical quality standards as the originator and must demonstrate equivalent clinical performance. For the patient, this means the same evidence-based benefits in terms of symptom control and safety, frequently at a lower cost to the healthcare system.
Olopatadine was first approved by the United States Food and Drug Administration (FDA) in 1996 as an ophthalmic antiallergic agent, and it has since been approved in more than 70 countries. The molecule is also marketed internationally under brand names such as Opatanol (European Union), Patanol (United States), Toredin, Optamont and various generic formulations including Olopatadine Misom. All of these products share the same active substance and concentration of 1 mg/ml for allergic conjunctivitis.
What Should You Know Before Using Olopatadine Misom?
Before starting Olopatadine Misom, tell your doctor if you have dry eye syndrome, corneal disease, wear contact lenses, are pregnant, are breastfeeding or are using other eye medications. Do not use this medicine if you are allergic to olopatadine or any of the excipients, or while you are breastfeeding.
As with any prescription medicine, Olopatadine Misom must only be used under the guidance of a qualified healthcare professional. A proper eye examination and history help confirm the diagnosis of allergic conjunctivitis and rule out other causes of red or itchy eyes, such as bacterial or viral conjunctivitis, keratitis, blepharitis or dry eye disease, which require different treatments.
Contraindications
You should not use Olopatadine Misom if any of the following apply to you:
- Known allergy to olopatadine or to any of the excipients listed in the “What does Olopatadine Misom contain?” section, including benzalkonium chloride, sodium chloride, disodium phosphate, hydrochloric acid, sodium hydroxide and water for injections
- Currently breastfeeding – olopatadine may be excreted into breast milk, and safety for the nursing infant has not been established
If you are unsure whether these contraindications apply to you, discuss your medical history with your doctor or pharmacist before starting treatment. True allergic reactions to olopatadine or its excipients are uncommon but can present as increased eye irritation, significant swelling of the eyelids or periorbital tissues, or skin redness and itching around the eyes after application. If any of these occur, stop using the drops and seek medical advice.
Warnings and Precautions
Talk to your doctor, pharmacist or nurse before using Olopatadine Misom if any of the following situations apply to you:
- Contact lens wearers: The preservative benzalkonium chloride present in Olopatadine Misom can be absorbed by soft (hydrogel) contact lenses and cause discolouration of the lens. Remove contact lenses before applying the drops and wait at least 15 minutes before reinserting them. Do not instil the drops while wearing lenses.
- Dry eye syndrome or corneal surface disease: Benzalkonium chloride can be irritating, especially if your tear film is already compromised. If you experience new or worsening stinging, burning or ocular pain after starting the drops, contact your doctor; a preservative-free antihistamine may be more appropriate.
- Severely damaged cornea: In very rare cases, phosphate-containing eye drops such as Olopatadine Misom have been associated with cloudy corneal patches (corneal calcification) due to calcium deposition in patients with pre-existing severe corneal damage. Report any new visual symptoms promptly.
- Concurrent ophthalmic treatments: If you use other eye drops or eye ointments, wait at least 5 minutes between different preparations. Eye ointments should always be applied last, since they can form a film that prevents absorption of subsequently applied drops.
- Unresolved or worsening symptoms: If your eye symptoms persist or worsen after several days of treatment, or if you experience new symptoms such as eye pain, sensitivity to light or blurred vision that does not resolve, contact your doctor for re-evaluation.
Use in Children
Olopatadine Misom can be used in children aged 3 years and older for seasonal allergic conjunctivitis. Paediatric clinical studies have shown a safety and efficacy profile comparable to that seen in adults, and the recommended dose in this age group is the same: one drop in the affected eye(s) twice daily. It should not be used in children under 3 years of age because the safety and efficacy of olopatadine have not been established in this group. For infants and toddlers under 3, your paediatrician may recommend non-pharmacological measures (allergen avoidance, cool compresses, artificial tears) or alternative medicines with established paediatric data.
In children able to hold their eye open and tolerate drops, application is generally straightforward. For more anxious or younger children, placing the drop in the inner corner of the closed eye and then asking the child to open the eye slowly allows the drop to enter the conjunctival sac. An accompanying adult should always be responsible for correct administration and for avoiding contamination of the bottle tip.
Pregnancy and Breastfeeding
If you are pregnant, think you may be pregnant or are planning to become pregnant, consult your doctor or pharmacist before using Olopatadine Misom. Animal reproductive studies with olopatadine have not shown teratogenic effects; however, human pregnancy data are limited. Because topically applied olopatadine produces very low systemic blood concentrations, the theoretical risk to the developing foetus is considered low, but your doctor will weigh the benefits of symptom control against any potential risk before recommending treatment during pregnancy.
Do not use Olopatadine Misom if you are breastfeeding. Olopatadine has been detected in the milk of lactating animals, and although human lactation data are lacking, the potential for unwanted effects in the nursing infant cannot be ruled out. If eye allergy treatment is essential during breastfeeding, discuss with your doctor whether to temporarily interrupt breastfeeding, use a different medicine or rely on non-pharmacological measures.
Driving and Operating Machinery
You may experience temporary blurred vision immediately after instillation of Olopatadine Misom. This is usually short-lived but can interfere with the ability to see clearly. Do not drive or operate machinery until your vision has returned to normal. If blurred vision persists, recurs frequently or is accompanied by other visual symptoms, contact your doctor. Any medicine that affects vision or alertness should be used with caution in situations that require sharp visual acuity, such as driving at night or in unfamiliar environments.
Important Information About Excipients
Olopatadine Misom contains the following excipients that deserve particular attention:
- Benzalkonium chloride (0.1 mg/ml): This quaternary ammonium preservative maintains the sterility of the solution during use but is absorbed by soft contact lenses and can discolour them. It may also damage the ocular surface in vulnerable patients. Remove contact lenses before each application and wait a minimum of 15 minutes before reinsertion. Report any persistent irritation, stinging or pain to your doctor.
- Phosphate buffer (approximately 3.3 mg phosphate per ml, corresponding to roughly 0.11 mg per drop): In rare cases, phosphate-containing eye drops have caused corneal calcification in patients with significantly damaged corneas. This risk is very low but should be considered when the medicine is used long-term or in patients with pre-existing corneal disease.
How Does Olopatadine Misom Interact with Other Drugs?
Olopatadine Misom has a low risk of clinically significant systemic drug interactions because only a small amount is absorbed into the bloodstream after topical application. However, practical interactions may occur when other eye medications are used at the same time; always space different eye drops by at least 5 minutes and apply eye ointments last.
When applied to the ocular surface, olopatadine reaches therapeutic concentrations in the conjunctival tissue while producing only negligible plasma levels. Pharmacokinetic studies have shown that systemic exposure after twice-daily ocular dosing is far below levels required for pharmacological activity elsewhere in the body. As a result, the ophthalmic formulation is not expected to interact significantly with oral or parenterally administered medications, and formal systemic drug–drug interaction studies have not been deemed necessary by regulatory authorities. No clinically relevant systemic interactions have been reported in long-term post-marketing surveillance.
Nevertheless, important practical considerations arise when Olopatadine Misom is used alongside other topical ophthalmic preparations. Concurrent use of multiple drops or ointments can affect how well each product is absorbed through the ocular surface. The following table summarises common scenarios and the recommended approach:
| Concurrent Medication | Type | Recommendation |
|---|---|---|
| Other eye drops (e.g. artificial tears, antibiotics, anti-glaucoma drops) | Ophthalmic solution or suspension | Wait at least 5 minutes between drops to prevent one product from washing out another |
| Eye ointments (e.g. antibiotic or lubricating ointments) | Ophthalmic ointment | Always apply ointments last, since they form a film that prevents absorption of subsequent drops |
| Oral antihistamines (e.g. cetirizine, loratadine, fexofenadine, desloratadine) | Systemic antihistamine | Can usually be used safely together; topical olopatadine has minimal systemic effect. Inform your doctor of all medications |
| Corticosteroid eye drops (e.g. dexamethasone, prednisolone, fluorometholone) | Ophthalmic anti-inflammatory | May be co-prescribed in severe allergic eye disease; allow 5 minutes between drops and use steroids only under specialist supervision |
| Intranasal corticosteroids (e.g. fluticasone, mometasone, budesonide) | Intranasal anti-inflammatory | Commonly used in patients with combined rhinoconjunctivitis; no direct interaction with ocular olopatadine |
| Contact lens solutions and preservatives | Ophthalmic care product | Remove lenses before applying drops; avoid simultaneous use with new lens disinfection cycles until lenses are fully rinsed |
Always tell your doctor or pharmacist about every medicine you use, including prescription drugs, over-the-counter medicines, herbal and nutritional supplements, and alternative eye preparations. Even though olopatadine has a favourable interaction profile, a full medication review helps your healthcare provider tailor the safest and most effective treatment plan for your individual situation, especially if you also take medicines that can affect the eyes – for example, certain anti-glaucoma drugs, oral isotretinoin or long-term antihistamine therapy.
What Is the Correct Dosage of Olopatadine Misom?
The recommended dose of Olopatadine Misom is one drop in the affected eye or eyes, twice daily (morning and evening), at intervals of approximately 8 hours. Do not exceed the prescribed dose and do not stop treatment without consulting your doctor.
Always use Olopatadine Misom exactly as your doctor or pharmacist has instructed. If any aspect of your treatment is unclear, ask before using the medicine for the first time. Correct dosing and proper instillation technique are the two most important factors for effective treatment and for minimising the risk of side effects or contamination.
Adults and Children (3 Years and Older)
Seasonal Allergic Conjunctivitis
Standard dose: 1 drop in the affected eye(s) twice daily
Timing: Morning and evening, approximately 8 hours apart
Duration: As directed by your doctor, typically for the duration of allergen exposure (often the entire pollen season)
Unless your doctor has specifically prescribed the drops for both eyes, apply Olopatadine Misom only to the eye or eyes showing allergic symptoms. Do not increase the frequency or number of drops per dose, as higher doses have not been shown to provide additional benefit and may increase the risk of local side effects.
Elderly Patients
No Dose Adjustment Required
No dose adjustment is necessary in elderly patients (over 65 years). Clinical studies and post-marketing experience have not shown differences in efficacy or safety between older and younger adults. However, elderly patients are more likely to have dry eye syndrome, reduced tear clearance or coexisting corneal disease, which can influence tolerability. If you are using other anti-glaucoma, anti-dry eye or lubricating preparations, your doctor may recommend spacing them carefully and monitoring the ocular surface over time.
Renal or Hepatic Impairment
No Dose Adjustment Required
Because olopatadine achieves very low systemic blood levels after topical ocular administration, no specific dose adjustment is required in patients with renal or hepatic impairment. Nevertheless, if you have severe liver or kidney disease, inform your doctor before starting any new medicine, including prescription eye drops, so that your overall treatment plan can be reviewed.
How to Apply the Eye Drops
Correct technique is essential for effective treatment and to avoid microbial contamination of the bottle. Follow these steps each time you use Olopatadine Misom:
- Wash your hands thoroughly with soap and water and dry them on a clean towel before handling the bottle
- Unscrew the cap from the bottle. If the tamper-evident seal on the neck of the bottle is loose or broken before first use, do not use the product – return it to your pharmacy
- Hold the bottle upside down between your thumb and middle finger, with the dropper tip pointing downward toward the eye
- Tilt your head back or lie down, and gently pull down your lower eyelid with a clean finger to create a small pocket between the lid and the eye
- Position the dropper tip close to but not touching the eye. Using a mirror can help you aim precisely
- Press gently on the base of the bottle to release a single drop into the pocket formed by the lower eyelid. Only a light press is needed; the bottle is designed to deliver the correct volume
- Do not allow the dropper tip to touch the eye, eyelid, eyelashes, skin or any other surface, as this may introduce micro-organisms into the remaining solution
- Close your eye gently and apply light pressure with a finger to the inner corner of the eye (against the side of the nose) for about 1 minute. This reduces the amount of medicine draining into the tear duct and minimises systemic absorption
- If both eyes require treatment, repeat the steps for the other eye
- Replace the cap securely immediately after use, without wiping the dropper tip
- If the drop misses the eye, try again with a fresh drop. Do not count a missed drop as a dose
Many people instinctively squeeze too hard and release more than one drop, wasting medicine and increasing the risk of contamination. If you struggle to deliver a single drop, ask your pharmacist about techniques or accessories (such as drop-guide devices) that can help. Caregivers assisting children or elderly relatives should ensure that the person is comfortable, supported and able to keep their head steady before instilling the drop.
Missed Dose
If you forget to apply a dose, use the drops as soon as you remember. However, if it is nearly time for your next scheduled dose, skip the missed one and continue with your normal dosing schedule. Do not apply a double dose to make up for a missed application. Consistent timing helps maintain steady therapeutic concentrations in the conjunctival tissue and provides the most uniform symptom relief throughout the day.
Overdose
If you accidentally apply too many drops, flush the eye thoroughly with lukewarm water or saline and do not apply any further drops until the next scheduled dose. Serious effects from local overdose are unlikely. If you or someone else – especially a child – accidentally swallows the solution from the bottle, contact your local poison control centre or emergency service immediately for assessment. Although the small volume in a single 5 ml bottle contains a limited amount of active substance, accidental ingestion should always be evaluated by a medical professional, particularly in small children.
Stopping Treatment
Do not stop using Olopatadine Misom without first consulting your doctor, even if your symptoms improve. Allergic conjunctivitis typically recurs as long as allergen exposure continues, and premature discontinuation can lead to a rapid return of itching, redness and tearing. Your doctor will advise you on the appropriate duration of treatment based on your allergen exposure profile (seasonal vs. perennial), severity of symptoms and individual response to therapy.
What Are the Side Effects of Olopatadine Misom?
The most common side effects of Olopatadine Misom are eye pain, eye irritation, dry eyes, abnormal sensation in the eye, headache and fatigue. Most reactions are mild and short-lived. Seek urgent medical attention if you experience severe eye swelling, sudden vision changes, difficulty breathing or signs of an allergic reaction.
Like all medicines, Olopatadine Misom can cause side effects, but not everyone will experience them. The side effects listed below are drawn from clinical trials with olopatadine 0.1% eye drops and from long-term post-marketing pharmacovigilance reports across multiple brands and markets. Most effects are localised to the eye and tend to be mild, transient and self-resolving, rarely requiring discontinuation of treatment.
- Severe eye swelling or marked swelling around the eyes
- Difficulty breathing or sudden shortness of breath
- Swelling of the face, lips, tongue or throat
- Sudden or significant loss of vision in one or both eyes
- Severe skin reactions, blistering or widespread rash
Common
May affect up to 1 in 10 people
- Eye: Eye pain, eye irritation, dry eye, abnormal sensation in the eye, eye discomfort
- General: Headache, tiredness (fatigue), dry nose, altered taste (dysgeusia)
Uncommon
May affect up to 1 in 100 people
- Eye: Blurred vision, decreased visual acuity, abnormal vision, corneal disorders, inflammation of the eye surface (keratitis) with or without epithelial damage, conjunctival inflammation or infection, eye discharge, photophobia (light sensitivity), increased tearing, itchy eyes, red eyes, eyelid disorders, eyelid itching/redness/swelling, crusting on the eyelids, foreign-body sensation
- General: Abnormal or reduced skin sensation (hypoaesthesia), dizziness, runny nose, dry skin, skin inflammation (dermatitis), burning sensation on the skin
Not Known
Frequency cannot be estimated from available data
- Eye: Eye swelling (periorbital or conjunctival oedema), corneal swelling, changes in pupil size
- General: Shortness of breath (dyspnoea), worsening of allergic symptoms, facial swelling, drowsiness, generalised weakness, nausea, vomiting, sinus infection (sinusitis), skin redness and itching
The majority of reported adverse reactions are ocular and relate either to the pharmacological action of olopatadine or to the preservative benzalkonium chloride. Systemic effects are uncommon due to the low plasma concentrations after topical application. In patients with severely damaged corneas, the phosphate content of Olopatadine Misom has been reported very rarely to contribute to the development of cloudy corneal patches caused by calcium deposition. Any new visual symptom or unexplained change in ocular comfort should be reported to your doctor without delay.
Reporting suspected adverse reactions after a medicine has been authorised is important because it allows continuous monitoring of the benefit-risk balance. Healthcare professionals and patients are encouraged to report suspected side effects to their national pharmacovigilance authority. In the United Kingdom, reports are made via the Yellow Card Scheme; in the United States, via the FDA MedWatch programme; in the European Union, via national competent authorities or the EMA EudraVigilance system. Other countries have their own national systems.
How Should You Store Olopatadine Misom?
Store Olopatadine Misom at room temperature (below 25°C) with no special storage requirements while the bottle is sealed. Once opened, discard the bottle after 4 weeks – even if solution remains – to minimise the risk of microbial contamination and eye infection.
Proper storage of ophthalmic preparations is essential for maintaining their sterility, chemical stability and therapeutic effectiveness. Contaminated eye drops can cause serious, sometimes sight-threatening infections such as bacterial keratitis, particularly in patients who wear contact lenses or who have compromised ocular surfaces. Follow these storage recommendations carefully:
- Keep out of the sight and reach of children to prevent accidental ingestion or misuse
- Check the expiry date printed on the bottle and carton (marked “EXP”). Do not use the medicine after the last day of the stated month
- No special storage temperature is required for the unopened product; store at room temperature and avoid direct sunlight or excessive heat
- Discard the bottle 4 weeks after first opening, regardless of whether solution remains. Preservative effectiveness decreases over time once the bottle is opened and used repeatedly, and the risk of microbial contamination rises
- Record the opening date on each bottle label and carton as soon as you open it, so that you can track when the 4-week period expires
- Disposal: Do not dispose of unused or expired medicine in household waste or wastewater. Return unused eye drops to your pharmacy for safe disposal, which helps protect the environment from pharmaceutical residues
Writing the date of first opening on the bottle is one of the single most important steps in safe eye drop use. Many patients forget when they opened a bottle and continue to use it well beyond the recommended 4-week window, which increases the risk of eye infection. Consider setting a reminder on your phone or calendar for 4 weeks after opening, and replace the bottle promptly when the reminder fires.
What Does Olopatadine Misom Contain?
The active substance is olopatadine. Each millilitre of solution contains olopatadine hydrochloride equivalent to 1 mg of olopatadine. The solution also contains several excipients, including the preservative benzalkonium chloride, a phosphate buffer and sodium chloride, all dissolved in water for injections.
Understanding the composition of your eye drops is important, especially if you have known sensitivities to specific excipients. The complete list of ingredients in Olopatadine Misom is summarised below. If you have experienced reactions to any of these substances in the past, discuss alternatives with your doctor or pharmacist before starting treatment.
| Ingredient | Role | Notes |
|---|---|---|
| Olopatadine hydrochloride | Active substance | Equivalent to 1 mg olopatadine per ml (0.1%) |
| Benzalkonium chloride | Preservative | 0.1 mg/ml; absorbed by soft contact lenses; may irritate dry or damaged eyes |
| Sodium chloride | Tonicity agent | Adjusts the osmolarity of the solution to match natural tears |
| Disodium phosphate dodecahydrate (E339) | Buffer | Maintains pH stability; provides approximately 3.3 mg phosphate per ml |
| Hydrochloric acid (E507) | pH adjustment | Used to achieve the target pH of the solution |
| Sodium hydroxide (E524) | pH adjustment | Used to achieve the target pH of the solution |
| Water for injections | Solvent | Purified, sterile water serving as the vehicle for the solution |
Olopatadine Misom is supplied as a clear, colourless ophthalmic solution in a 5 ml plastic dropper bottle with a screw cap and tamper-evident seal. Pack sizes may include one bottle or three bottles of 5 ml; not all pack sizes may be marketed in every country.
How Does Olopatadine Work in the Body?
Olopatadine has a unique dual mechanism of action: it blocks histamine H1 receptors on conjunctival cells and simultaneously stabilises mast cells, preventing the release of histamine and other inflammatory mediators. This two-pronged approach provides both rapid symptom relief and ongoing prophylactic protection during allergen exposure.
When an allergen such as pollen or pet dander reaches the eye, it binds to immunoglobulin E (IgE) antibodies on the surface of mast cells in the conjunctival tissue. This binding triggers rapid mast cell degranulation – the release of pre-formed mediators including histamine, tryptase, prostaglandin D2 and a range of cytokines. Histamine binds to H1 receptors on sensory nerve endings (producing itching), on small blood vessels (causing dilation and visible redness) and on epithelial cells (promoting swelling through increased vascular permeability).
Olopatadine interrupts this allergic cascade at two critical points. As a selective H1-receptor antagonist, it competes with histamine for binding at the receptor level and directly blocks the signals responsible for itch, redness and swelling. Unlike older first-generation antihistamines, olopatadine has high selectivity for the H1 receptor and very limited affinity for anticholinergic, anti-serotonergic or adrenergic receptors, which greatly reduces unwanted systemic effects. In animal and human conjunctival models, olopatadine demonstrates rapid H1 blockade with an effect detectable within minutes of application.
As a mast cell stabiliser, olopatadine inhibits the calcium-dependent degranulation of conjunctival mast cells, preventing the initial release of histamine, tryptase and pro-inflammatory cytokines. This preventive component of the mechanism means that consistent use during allergen exposure can dampen the overall inflammatory response, potentially providing better symptom control than medicines that only block receptors without addressing mediator release. Mast cell stabilisation contributes to the longer-term tolerability of chronic use through the allergy season.
After topical administration, olopatadine penetrates the conjunctival tissue to reach therapeutic local concentrations within 30 minutes of instillation. Systemic plasma levels remain far below those required for pharmacological activity in other tissues, which explains the very low incidence of sedation or anticholinergic effects typically associated with first-generation systemic antihistamines. The duration of action of approximately 8 hours supports the twice-daily dosing regimen, covering the daytime allergen exposure window for most patients with seasonal allergic conjunctivitis.
Olopatadine also has anti-inflammatory properties that extend beyond classical antihistamine activity. Studies have demonstrated that it reduces eosinophil infiltration, suppresses selected pro-inflammatory cytokines (such as IL-6 and IL-8) in human conjunctival epithelial cells, and decreases leukotriene synthesis. These additional effects likely contribute to the sustained clinical benefit observed in real-world use, where patients often experience progressive improvement in symptoms over the first 1 to 2 weeks of continuous therapy.
Frequently Asked Questions About Olopatadine Misom
Olopatadine Misom is an antihistamine eye drop used to treat the signs and symptoms of seasonal allergic conjunctivitis (eye allergy). It relieves itching, redness, tearing and swelling of the eyes caused by allergens such as pollen, dust mites and animal dander. It works by blocking histamine H1 receptors and by stabilising mast cells in the eye, providing a dual mechanism of relief that acts both on existing symptoms and on preventing further mediator release.
You should remove contact lenses before applying Olopatadine Misom and wait at least 15 minutes before reinserting them. The preservative benzalkonium chloride in the solution can be absorbed by soft contact lenses and may cause discolouration of the lens and irritation of the eye. If you have dry eyes, corneal problems or a history of benzalkonium sensitivity, discuss preservative-free alternatives with your doctor.
The recommended dose is one drop in the affected eye or eyes twice daily, in the morning and evening, approximately 8 hours apart. Do not use it more often than prescribed. Apply the drops to both eyes only if your doctor has specifically instructed you to do so. Consistent timing helps maintain steady therapeutic levels in the conjunctival tissue throughout the day and night.
Common side effects include eye pain, eye irritation, dry eyes, an abnormal sensation in the eye and eye discomfort. General side effects include headache, tiredness, dry nose and altered taste. These effects are usually mild and temporary. Seek immediate medical attention if you experience significant eye swelling, sudden vision changes, swelling of the face or throat, difficulty breathing or a severe skin reaction.
Olopatadine Misom can be used in children aged 3 years and older for seasonal allergic conjunctivitis, at the same dose as adults (one drop twice daily). It should not be used in children under 3 years because there is insufficient data on safety and efficacy in this age group. Always follow your doctor's dosage instructions and supervise younger children during application to ensure proper technique.
Olopatadine Misom eye drops should be discarded 4 weeks after first opening the bottle, even if solution remains. This is to prevent microbial contamination and potential eye infection. Write the date of first opening on the bottle label and carton. Store the unopened bottle at room temperature; no special storage conditions are required. Do not use the drops after the expiry date printed on the packaging.
Discuss pregnancy and breastfeeding with your doctor before using Olopatadine Misom. Animal data suggest no teratogenic risk, but human pregnancy data are limited. Because systemic absorption after topical use is very low, the theoretical risk to the foetus is considered low, but treatment is only recommended if the potential benefit clearly outweighs any risk. Olopatadine Misom should not be used while breastfeeding, as the medicine may pass into breast milk and safety for the nursing infant has not been established.
Olopatadine typically begins to relieve itching and redness within a few minutes of application, with peak conjunctival concentrations reached in around 30 minutes. The duration of action is approximately 8 hours per dose, which is why the drops are used twice daily. Some patients experience progressive improvement in symptoms over the first 1 to 2 weeks of continuous use, as the mast-cell stabilising effect builds up with regular dosing.
References
This article is based on international medical guidelines, regulatory documentation and peer-reviewed scientific sources. All clinical claims reflect current best-practice guidance and evidence-based medicine.
- European Medicines Agency (EMA). Olopatadine – Summary of Product Characteristics (SmPC). EMA product information database. Accessed January 2026.
- U.S. Food and Drug Administration (FDA). Olopatadine Hydrochloride Ophthalmic Solution – Prescribing Information. FDA Orange Book and label repository. Accessed January 2026.
- British National Formulary (BNF). Olopatadine. NICE BNF monograph, London. Accessed January 2026.
- Leonardi A, Bogacka E, Fauquert JL, et al. Ocular allergy: recognizing and diagnosing hypersensitivity disorders of the ocular surface. Allergy. 2012;67(11):1327–1337. doi:10.1111/all.12009
- Bielory L, Friedlaender MH. Allergic conjunctivitis. Immunology and Allergy Clinics of North America. 2008;28(1):43–58. doi:10.1016/j.iac.2007.12.005
- Abelson MB, Spitalny L. Combined analysis of two studies using the conjunctival allergen challenge model to evaluate olopatadine hydrochloride, a new ophthalmic antiallergic agent with dual activity. American Journal of Ophthalmology. 1998;125(6):797–804.
- Rosenwasser LJ, O'Brien T, Weyne J. Mast cell stabilization and anti-histamine effects of olopatadine ophthalmic solution: a review of pre-clinical and clinical research. Current Medical Research and Opinion. 2005;21(9):1377–1387.
- World Allergy Organization (WAO). White Book on Allergy. Milwaukee: WAO; 2013.
- American Academy of Ophthalmology (AAO). Preferred Practice Pattern: Conjunctivitis. AAO Clinical Guidelines. Updated 2023.
- Bielory L, Ghafoor S. Histamine receptors and the conjunctiva. Current Opinion in Allergy and Clinical Immunology. 2005;5(5):437–440.
- European Academy of Allergy and Clinical Immunology (EAACI). Guidelines on Allergic Rhinitis and Ocular Allergy. Zurich: EAACI; 2023.
Editorial Team
This article has been written and reviewed by the iMedic Medical Editorial Team, a multidisciplinary group of licensed specialist physicians with documented expertise in ophthalmology, allergy medicine and clinical pharmacology.
Medical Writers
Board-certified physicians specialising in ophthalmology, allergology and clinical pharmacology with documented academic and clinical experience in ocular surface disease.
Medical Reviewers
An independent review board ensures clinical accuracy and adherence to international guidelines (EAACI, AAO, WHO) and to the GRADE evidence framework.
All content follows the GRADE evidence framework and is reviewed against current international guidelines. We have no commercial funding or pharmaceutical sponsorship. For more information, see our editorial standards and medical team pages.